Ads
related to: novartis
Search results
US pharma giant Cencora says Americans' health information stolen in data breach
TechCrunch· 6 days agoU.S. pharmaceutical giant Cencora says it is notifying affected individuals that their personal and...
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further...
WJET - WFXP Erie· 5 days ago...atrasentan is a potent, selective ETA receptor antagonist with potential to reduce persistent...
SageView Advisory Group LLC Acquires 718 Shares of Novartis AG (NYSE:NVS)
ETF DAILY NEWS· 2 days agoSageView Advisory Group LLC boosted its stake in shares of Novartis AG (NYSE:NVS – Free Report) by 30.6% in the fourth quarter, according to the company in its most recent ...
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing...
FOX 23 News Albany· 5 days agoNovartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G...
Novartis (NVS) Presents Positive Data on Renal Drugs at ERA
Zacks· 3 days agoNovartis (NVS) presents data on Fabhalta in adult patients with C3 glomerulopathy and atrasentan in...
Novartis and Clarius partner for psoriatic arthritis care in Canada
Medical Device Network via Yahoo Finance· 2 days agoNovartis Pharmaceuticals Canada has partnered with Clarius Mobile Health to help improve access to...
Novartis’ atrasentan shows to reduce proteinuria in Phase III IgAN trial
Clinical Trials Arena via Yahoo Finance· 3 days agoNovartis has unveiled interim results from the Phase III ALIGN clinical trial where atrasentan...
Dr. Reddy’s and Novartis sign distribution agreement for anti-diabetes products
Pharmaceutical Technology via Yahoo Finance· 3 days agoDr. Reddy's Laboratories' Russian subsidiary has signed an agreement with Novartis Pharma to carry...
Campbell hires lawyer to head affordability unit - The Boston Globe
The Boston Globe· 1 day agoA former longtime executive at the Swiss drug giant Novartis will become the new chief executive of...
Novartis to seek approvals in two rare kidney diseases after positive Phase 3 trials
Endpoints News· 5 days agoNovartis is building out its rare kidney disease portfolio with two batches of Phase 3 data at the...